Keywords: patient, dosing, begins, ph, ii, davanat, trial

Patient dosing begins in Ph II Davanat trial

Article | 11 December 2006

The USA's Pro-Pharmaceuticals has started dosing patients in a Phase II open-label, multicenter trial of its carbohydrate-based chemosensitizer, Davanat, with ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Drugs

Avastin

bevacizumab

Carac

Fluorouracil

Efudex

Go to drug listing